Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

•Bromodomain and extra-terminal domain (BET) proteins may play a pivotal role in cancer.•CC-90010 is a potent, reversible, oral BET inhibitor with a long terminal half-life, which enables less frequent dosing.•CC-90010 was well tolerated and had encouraging antitumor activity in heavily pretreated patients with advanced malignancies. BackgroundBromodomain and extra-terminal (BET) proteins are epigenetic readers that regulate expression of genes...